With a large total addressable market, awareness through a strong direct to consumer advertising ... I/we have a beneficial long position in the shares of TARS either through stock ownership ...
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) is advancing its pipeline with a phase 2 trial for ocular rosacea and a Lyme disease prevention program, indicating strong future growth potential.
See what stocks are receiving strong buy ratings from top-rated analysts ... Tarsus Pharmaceuticals has an average volume of 567.6K. Read More on TARS: Tarsus Pharmaceuticals NewsMORE Related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback